Personalized mRNA cancer vaccines for dogs designed computationally from each dog's tumor genome to target cancer-driving mutations.
Gamgee's platform sequences a dog's tumor and healthy DNA, identifies the mutations driving the cancer, and designs a personalized mRNA vaccine protocol administered by a veterinary oncologist with ongoing response monitoring. The company manages the entire process end-to-end from intake review and vet outreach through tissue collection, genomic analysis, and vaccine creation. Gamgee is currently running clinical trials in Australia and accepting registrations of interest worldwide. Its first product is designated ze-ets-001. Gamgee is a product of Gamgee.
For people
For agents
Nothing listed yet.